cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Oric Pharmaceuticals
12 own
11 watching
Current Price
$7.67
$-0.41
(-5.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
358.19M
52-Week High
52-Week High
16.65000
52-Week Low
52-Week Low
4.89000
Average Volume
Average Volume
0.61M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization358.19M
icon52-Week High16.65000
icon52-Week Low4.89000
iconAverage Volume0.61M
iconDividend Yield--
iconP/E Ratio--
What does the Oric Pharmaceuticals do?
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. Profound advancements in oncology drug development have expanded the treatment options available to patients, yet therapeutic resistance and relapse continue to limit the efficacy and duration of clinical benefit of such treatments. Collectively, our founders and management team have a decades-long heritage of identifying and characterizing resistance mechanisms in oncology, having discovered and developed groundbreaking medicines at companies such as Ignyta, Medivation, Aragon and Genentech. At ORIC, our fully integrated discovery and development team is advancing a diverse pipeline of innovative therapies designed to counter resistance mechanisms in cancer by leveraging our expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. We were incorporated in Delaware in August 2014. Our principal executive offices are located at 240 E. Grand Avenue, 2nd Floor, South San Francisco, California 94080. Our telephone number is (650) 388-5600.Our website address is www.oricpharma.com.
Read More
How much money does Oric Pharmaceuticals make?
News & Events about Oric Pharmaceuticals.
Globe Newswire
10 months ago
Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital Pro forma cash and investments expected to fund current operating plan into late 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 26, 2023 (GLOBE ...
Globe Newswire
1 year ago
Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023:ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Development candidate selected for PLK4 synthetic lethal breast cancer program Cash and investments of $228 ...
PR Newswire
1 year ago
Thinking about buying stock in Thermogenesis Holdings, ProQR Therapeutics, Grom Social, ORIC Pharmaceuticals, or Acasti Pharma? Thinking about buying stock in Thermogenesis Holdings, ProQR Therapeutics, Grom Social, ORIC Pharmaceuticals, or Acasti Pharma? PR Newswire NEW YORK, Dec. 22, 2022 NEW...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented preclinical ORIC-533 data demonstrating a potential ...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a preclinical poster presentation on ORIC-533 ...
Frequently Asked Questions
Frequently Asked Questions
What is Oric Pharmaceuticals share price today?
plus_minus_icon
Can Indians buy Oric Pharmaceuticals shares?
plus_minus_icon
How can I buy Oric Pharmaceuticals shares from India?
plus_minus_icon
Can Fractional shares of Oric Pharmaceuticals be purchased?
plus_minus_icon
What are the documents required to start investing in Oric Pharmaceuticals stocks?
plus_minus_icon
What is today’s traded volume of Oric Pharmaceuticals?
plus_minus_icon
What is today’s market capitalisation of Oric Pharmaceuticals?
plus_minus_icon
What is the 52-Week High and Low Range of Oric Pharmaceuticals?
plus_minus_icon
What percentage is Oric Pharmaceuticals down from its 52-Week High?
plus_minus_icon
What percentage is Oric Pharmaceuticals up from its 52-Week Low?
plus_minus_icon
Current Price
$7.67
$-0.41
(-5.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
VERRICA PHARMACEUTICALS INC
VERRICA PHARMACEUTICALS INC
$6.65
$-0.14 (-2.06 %)
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS INC
$16.87
$0.65 (4.01 %)
Cullinan Oncology Inc
Cullinan Oncology Inc
$19.25
$0.36 (1.91 %)
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
$0.66
$-0.01 (-1.64 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
VERRICA PHARMACEUTICALS INC
VERRICA PHARMACEUTICALS INC
$6.65
$-0.14 (-2.06 %)
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS INC
$16.87
$0.65 (4.01 %)
Cullinan Oncology Inc
Cullinan Oncology Inc
$19.25
$0.36 (1.91 %)
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
$0.66
$-0.01 (-1.64 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00